Abstract
Biomarkers defining biological age are typically laborious or expensive to assess. Instead, in the current study, we identified parameters based on standard laboratory blood tests across metabolic, cardiovascular, inflammatory, and kidney functioning that had been assessed in the Berlin Aging Study (BASE; n = 384) and Berlin Aging Study II (BASE-II, n = 1,517). We calculated biological age using those 12 parameters that individually predicted mortality hazards over 26 years in BASE.
In BASE, older biological age was associated with more physician-observed morbidity and higher mortality hazards, over and above the effects of chronological age, sex, and education. Similarly, in BASE-II, biological age was associated with physician-observed morbidity and subjective health, over and above the effects of chronological age, sex, and education as well as alternative biomarkers including telomere length, DNA methylation age, skin age, and subjective age. We discuss the importance of biological age as one indicator of aging.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
Financial support for the Berlin Aging Study came from the Max Planck Society; the Free University of Berlin; the German Federal Ministry for Research and Technology (1989-1991, 13 TA 011 & 13 TA 011/A); the German Federal Ministry for Family, Senior Citizens, Women, and Youth (1992-1998, 314-1722-102/9 & 314-1722-102/9a); and the Berlin-Brandenburg Academy of Sciences‟ Research Group on Aging and Societal Development (1994-1999). This work also reports data from the BASE-II project, which was supported by the German Federal Ministry of Education and Research (Bundesministerium fuer Bildung und Forschung, BMBF) under grant numbers #01UW0808; #16SV5536K, #16SV5537, #16SV5538, #16SV5837; #01GL1716A; and #01GL1716B. Another source of funding is the Max Planck Institute for Human Development, Berlin, Germany. Additional contributions (e.g., equipment, logistics, personnel) are made from each of the other participating sites. This work was supported by a grant of the Deutsche Forschungsgemeinschaft (grant number DE 842/7-1).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The Ethics Commission of the Berlin Chamber of Physicians (Aerztekammer Berlin) approved the BASE study prior to the first assessments in 1990 (approvals were not numbered at that time). The Ethics Committee of the Charite University hospital approved the BASE-II study (approval number EA2/029/09).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
↵* shared-last authors
Data Availability
The data can be requested from the steering committee of the Berlin Aging Study and the Berlin Aging Study II. Further details about the procedure can be obtained at https://www.base-berlin.mpg.de/de and www.base2.mpg.de.
